Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced topline data from the Phase 2b SOLANO study of ION449 (AZD8233) for hypercholesterolemia (high cholesterol levels).…
Ionis ION449 (AZD8233) Met Primary Endpoint in Phase 2b SOLANO Study for Patients with Hypercholesterolemia; Will Not Advance into Phase 3 Development Based on Pre-specified Criteria
September 23, 5:01 AM
Ionis Pharmaceuticals, Inc.
There’s ‘Outsized’ Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
September 9, 11:22 AM
Morgan Stanley has assumed coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with an Overweight (previously Underweight) rating and a price target of $57 from…
September 9, 7:59 AM
Morgan Stanley analyst Andrew Galler upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Underweight to Overweight and raises the price target from $30 to $57.
September 7, 5:45 PM
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…
Ionis and Astrazeneca’s Eplontersen Demonstrated a Statistically Significant and Clinically Meaningful Change From Baseline for Co-primary and Secondary Endpoints at 35 Weeks vs External Placebo Group
September 7, 4:50 AM
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a planned 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
August 10, 8:45 AM
RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $67 to $64.
August 4, 5:54 AM
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.